Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix

dc.contributor.author
Mendaza, Saioa
dc.contributor.author
Fernández Irigoyen, Joaquín
dc.contributor.author
Santamaría, Enrique
dc.contributor.author
Zudaire, Tamara
dc.contributor.author
Guarch Troyas, Rosa María
dc.contributor.author
Guerrero-Setas, David
dc.contributor.author
Vidal-Bel, August
dc.contributor.author
Santos-Salas, José
dc.contributor.author
Matias-Guiu, Xavier, 1958-
dc.contributor.author
Ausin, Karina
dc.contributor.author
Díaz de Cerio, María José
dc.contributor.author
Martín-Sánchez, Esperanza
dc.date.issued
2020-12-11T15:08:44Z
dc.date.issued
2020-12-11T15:08:44Z
dc.date.issued
2020-03-19
dc.date.issued
2020-12-11T15:08:44Z
dc.identifier
1661-6596
dc.identifier
https://hdl.handle.net/2445/172684
dc.identifier
701336
dc.identifier
32204550
dc.description.abstract
The tumor-suppressor protein p16 is paradoxically overexpressed in cervical cancer (CC). Despite its potential as a biomarker, its clinical value and the reasons for its failure in tumor suppression remain unclear. Our purpose was to determine p16 clinical and biological significance in CC. p16 expression pattern was examined by immunohistochemistry in 78 CC cases (high-grade squamous intraepithelial lesions (HSILs) and squamous cell carcinomas of the cervix -SCCCs). CC cell proliferation and invasion were monitored by real-time cell analysis and Transwell® invasion assay, respectively. Cytoplasmic p16 interactors were identified from immunoprecipitated extracts by liquid chromatography-tandem mass spectrometry, and colocalization was confirmed by double-immunofluorescence. We observed that SCCCs showed significantly more cytoplasmic than nuclear p16 expression than HSILs. Importantly, nuclear p16 absence significantly predicted poor outcome in SCCC patients irrespective of other clinical parameters. Moreover, we demonstrated that cytoplasmic p16 interacted with CDK4 and other unreported proteins, such as BANF1, AKAP8 and AGTRAP, which could sequester p16 to avoid nuclear translocation, and then, impair its anti-tumor function. Our results suggest that the absence of nuclear p16 could be a diagnostic biomarker between HSIL and SCCC, and an independent prognostic biomarker in SCCC; and explain why p16 overexpression fails to stop CC growth.
dc.format
17 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/ijms21062125
dc.relation
International Journal of Molecular Sciences, 2020, vol. 21, num. 6, p. 2125
dc.relation
https://doi.org/10.3390/ijms21062125
dc.rights
cc-by (c) Mendaza, Saioa et al., 2020
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Patologia i Terapèutica Experimental)
dc.subject
Cèl·lules canceroses
dc.subject
Càncer de coll uterí
dc.subject
Diagnòstic
dc.subject
Cancer cells
dc.subject
Cervix cancer
dc.subject
Diagnosis
dc.title
Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.